Tsumura & Co (4540) Price & Analysis

Compare

3 Followers

4540 Stock Chart & Stats

¥3599.00

¥9.00(0.19%)

At close: Jan 08 4:00 PM EST

¥3599.00

¥9.00(0.19%)

Day’s Range― - ―

52-Week Range¥3,306.00 - ¥4,568.00

Previous CloseN/A

Volume145.30K

Average Volume (3M)448.06K

Market Cap

¥309.78B

Enterprise Value¥366.91B

Total Cash (Recent Filing)¥69.48B

Total Debt (Recent Filing)¥135.41B

Price to Earnings (P/E)10.4

Beta0.52

Next Earnings

May 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.3%

Share Statistics

EPS (TTM)142.95

Shares Outstanding76,758,360

10 Day Avg. Volume373,220

30 Day Avg. Volume448,060

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)1.09

Price to Sales (P/S)1.81

P/FCF Ratio52.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Profitability And MarginsSustained high gross and healthy net margins reflect durable product economics in Kampo formulations. Strong margins provide structural capacity to fund R&D, maintain manufacturing quality and support pricing flexibility versus peers, underpinning long-term operating resilience.

Consistent Multi‑year Revenue GrowthMulti-year top-line expansion demonstrates persistent demand for prescription Kampo products and successful market penetration. Consistent revenue growth supports scale advantages in manufacturing and distribution, reducing unit costs and reinforcing long-term market position.

Reimbursed Prescription Business ModelEarnings driven by reimbursed prescription products creates a structurally sticky revenue base tied to healthcare reimbursement and physician prescribing. This model yields predictable demand, high barriers to entry, and stable channel relationships that persist across economic cycles.

Bears Say

Negative Free Cash FlowA sustained swing to materially negative free cash flow increases reliance on external financing and raises execution risk for capex or acquisitions. Weak cash conversion constrains flexibility to self-fund growth, dividends or margin-enhancing investments over the medium term.

Rising LeverageA marked increase in debt reduces financial headroom and raises interest and refinancing exposure. Higher leverage limits optionality for strategic moves and amplifies downside in earnings shocks, making capital allocation and long-term stability more sensitive to cash‑flow variability.

Eroding Profitability MetricsDeclining margins and a step‑down in ROE suggest rising cost pressure or mix shifts that weaken earnings quality. If persistent, this trend can limit reinvestment returns and make it harder to translate revenue growth into shareholder value over multiple reporting periods.

Tsumura & Co News

Tsumura Updates Q3 FY2026 Results and Expands Consolidation of Chinese Herbal Subsidiary

Tsumura & Co ( ($JP:4540) ) has issued an announcement. Tsumura & Co. released supplementary materials for the...

11d ago

Tsumura Posts Higher Sales but Lower Profits, Keeps Full-Year Forecast and Dividend Plan Intact

An announcement from Tsumura & Co ( ($JP:4540) ) is now available. Tsumura & Co. reported consolidated net...

11d ago

Is TSMRF a Buy, Before Earnings?

Tsumura & Co (TSMRF) is scheduled to report 3rd quarter earnings on 02/06/2026. Regarding Q3 estimates, Wall Street...

12d ago

Tsumura Confirms It Is Weighing Reported Yomeishu Take-Private but Says No Decision Yet

Tsumura & Co ( ($JP:4540) ) has provided an update. Tsumura & Co. clarified that recent reports in...

14d ago

Tsumura Secures ¥50 Billion Syndicated Loan with Financial Covenants for Growth Investment

Tsumura & Co ( ($JP:4540) ) has provided an update. Tsumura & Co. has entered into a large...

1M ago

Tsumura Completes Acquisition of Shanghai Hongqiao Stake

Tsumura & Co ( ($JP:4540) ) has issued an announcement. Tsumura & Co. has completed the acquisition of...

3M ago

Tsumura & Co. Revises Medium-Term Plan with Higher Profit Targets

Tsumura & Co ( ($JP:4540) ) just unveiled an update. Tsumura & Co. has revised its Medium-Term Management...

3M ago

Tsumura & Co. Revises Earnings and Dividend Forecasts for FY 2026

Tsumura & Co ( ($JP:4540) ) has shared an announcement. Tsumura & Co. has revised its earnings and...

3M ago

Tsumura & Co. Reports Mixed Financial Results Amid Strategic Adjustments

The latest update is out from Tsumura & Co ( ($JP:4540) ). Tsumura & Co. reported a slight...

3M ago

TSMRF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Tsumura & Co (TSMRF) is scheduled to report 2nd quarter earnings on 11/10/2025. Regarding Q2 estimates, Wall Street...

3M ago

4540 FAQ

What was Tsumura & Co.’s price range in the past 12 months?

Tsumura & Co. lowest stock price was ¥3306.00 and its highest was ¥4568.00 in the past 12 months.

What is Tsumura & Co.’s market cap?

Tsumura & Co.’s market cap is ¥309.78B.

When is Tsumura & Co.’s upcoming earnings report date?

Tsumura & Co.’s upcoming earnings report date is May 12, 2026 which is in 85 days.

How were Tsumura & Co.’s earnings last quarter?

Tsumura & Co. released its earnings results on Feb 06, 2026. The company reported ¥142.95 earnings per share for the quarter, beating the consensus estimate of ¥90.935 by ¥52.015.

Is Tsumura & Co. overvalued?

According to Wall Street analysts Tsumura & Co.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tsumura & Co. pay dividends?

Tsumura & Co. pays a Semiannually dividend of ¥76 which represents an annual dividend yield of 3.3%. See more information on Tsumura & Co. dividends here

What is Tsumura & Co.’s EPS estimate?

Tsumura & Co.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tsumura & Co. have?

Tsumura & Co. has 76,758,360 shares outstanding.

What happened to Tsumura & Co.’s price movement after its last earnings report?

Tsumura & Co. reported an EPS of ¥142.95 in its last earnings report, beating expectations of ¥90.935. Following the earnings report the stock price went up 1.353%.

Which hedge fund is a major shareholder of Tsumura & Co.?

Currently, no hedge funds are holding shares in JP:4540

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Tsumura & Co.

Tsumura & Co. (4540) is a leading Japanese pharmaceutical company specializing in traditional herbal medicine, also known as Kampo medicine. Established in 1893, the company develops, manufactures, and sells a wide range of Kampo products, which are derived from natural herbal ingredients. Tsumura operates primarily in the healthcare sector, focusing on providing effective and safe therapeutic solutions that align with Japan's rich history of herbal medicine. In addition to Kampo formulations, the company is involved in research and development of new pharmaceuticals and operates in the field of health foods.